drugset
drugset / Trial / NCT04226690

Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products

NCT04226690 ↗

Phase 1 Completed 24 enrolled Yale University Connecticut Pharmaceutical Solutions · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This proposal aims to systematically examine the safety and pharmacokinetic/pharmacodynamic profile and the physiologic, neuroendocrine and behavioral stress and pain responses to acute single doses and repeated dosing of oral tablet formulation of natural Cannabidiol (CBD) alone and in combination with Tetrahydrocannabinol and matched Placebo (PLA).

Timeline

Start
2022-11-15
Primary completion
2023-12-15
Completion
2023-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified — Oral
Subject Dronabinol Other / unclassified — Oral

Indications

No indication recorded.